Introduction
Symptomatic, severe tricuspid regurgitation (TR) and right ventricular (RV) dysfunction are closely associated, 1 and lead to right-sided heart failure (HF) with repeat hospitalizations and annulus dilatation. Later reoperation for persistent TR is a high-risk procedure and spontaneous recovery of severe TR after correction of left-sided valvulopathy is less predictable. 7, 8 In addition, severe TR can develop late after mitral valve surgery. 8, 9 Recently, the transcatheter edge-to-edge repair method, which was originally developed for the treatment of severe mitral regurgitation (MR), has been successfully applied for the treatment of severe TR.
10 -12 Some case reports as well as small case series demonstrated technical feasibility, procedural safety, and a promising early clinical benefit.
13 -15 However, the results beyond 30 days concerning safety, durability and clinical outcome are unknown. Therefore, the current study investigated the 6-month outcome of HF patients who were treated with the transcatheter edge-to-edge TV repair technique for isolated severe TR or in combination with severe MR.
Methods

Patients
We screened 95 patients with right-sided HF and moderate to severe TR for eligibility of an interventional TV repair approach. Patients were excluded for several reasons: only moderate TR and tricuspid annulus <40 mm in screening transoesophageal echocardiography (TOE); tricuspid anatomy deemed unsuitable for edge-to-edge repair with extremely large coaptation gaps impossible to bridge with the device; any degree of mitral or tricuspid valve stenosis; poor echocardiographic visibility during screening TOE; patients recommended by an interdisciplinary heart team to undergo a surgical procedure; any transtricuspid RV lead hindering leaflet adaption and thus the predominant reason for TR; severe aortic stenosis or patients undergoing a transcatheter aortic valve replacement procedure for this reason; patients undergoing heart transplantation. The assessment of anatomic unsuitability was not pre-specified but evolved during the experience. Fifty consecutive, eligible patients were treated for symptomatic severe TR from March to November 2016 at the university hospital of the Ludwig-Maximilians University, Munich, and at the Heart Center Leipzig, University of Leipzig, both in Germany. Fourteen patients were treated for isolated TR, while 36 patients received a combined transcatheter edge-to-edge repair procedure for MR and TR. All patients had clinical signs of right-sided HF such as peripheral oedema, ascites, pleural effusion, jugular vein distension, congestive renal failure, fatigue, shortness of breath, or a combination of these. Patients were in New York Heart Association (NYHA) functional class III or IV despite optimal medical therapy and were deemed at prohibitive surgical risk by an interdisciplinary heart team. We included one patient with moderate TR and tricuspid annulus dilatation of 46 mm. A RV lead was present in 14 out of 50 patients. All patients provided written informed consent. The local ethics committees approved the data analysis of patients treated with edge-to-edge TV repair.
Procedure
The transcatheter edge-to-edge repair system (MitraClip ® , Abbott Vascular, Santa Clara, CA, USA) was introduced transfemorally under general anaesthesia in all cases. The intervention was guided by twoand three-dimensional TOE and transthoracic echocardiography (TTE). Additional fluoroscopy was performed in all cases. In the case of combined MR and TR repair, we first crossed the interatrial septum to treat MR; subsequently, TR was treated in the same procedure. The number of implanted clips was left to the discretion of the treating physician to achieve a substantial reduction in TR and MR.
Follow-up
The outcome and impact of the procedure were assessed with echocardiographic, safety and clinical parameters at 30 days and 6 months in our or affiliated centres in comparison to the pre-procedural baseline status. Safety of the procedure was evaluated with the occurrence of major adverse cardiac and cerebrovascular events during follow-up. Standardized assessment of symptoms and quality of life was done with NYHA functional class and the Minnesota Living with Heart Failure Questionnaire (MLHFQ) score, respectively. In addition, we measured the 6-minute walk distance (6MWD). We determined N-terminal pro-B-type natriuretic peptide (NT-proBNP) as an objective, standardized laboratory parameter for HF. The primary objective was to define the mid-term device safety and durability in TR reduction after 6 months. Secondary objectives were improvements in clinical and laboratory parameters as well as the need for repeat interventions and hospitalizations. The 30-day results of the first 18 patients, treated at the Ludwig-Maximilians University, Munich, have recently been published elsewhere. 14 
Echocardiography
Severity of TR was evaluated at baseline, before discharge, after 30 days and 6 months with TTE. There was no core lab analysis or blinding, both sites evaluated their patients according to current international recommendations for the assessment of native valve regurgitation and right heart chamber quantification. 16 -18 Intraprocedural assessment was performed by an echocardiography specialist with TOE before and after clip placement to evaluate procedural success at each site. The echocardiographer responsible for TTE assessment was not present during the procedure. Evaluation of TR comprised coaptation gap width, vena contracta width, TR volume and effective regurgitant orifice area according to the proximal isovelocity surface area (PISA) method, inferior vena cava width, and presence of systolic flow reversal in hepatic veins. The synthesis of all available parameters led to a grading of TR comprising four stages: mild (1+), moderate (2+), severe (3+), and massive (4+).
14 Massive, 'torrent' TR grade 4+ was introduced recently to account for TR types with a very large vena contracta and effective loss of TV gradient.
Statistics
Continuous variables are presented as means with standard deviations, or median with interquartile range (IQR). We applied Fisher's exact test to compare categorical variables. For continuous variables, statistical testing was done with either the paired t-test (normal distribution, paired), the Wilcoxon test (no normal distribution, paired), or the Mann-Whitney test (no normal distribution, unpaired). A P-value of <0.05 was considered statistically significant. Isolated and combined repair procedures were also analysed separately.
Results
Transcatheter edge-to-edge TV repair was attempted in 50 consecutive patients with a mean age of 77 ± 8 years who were deemed at high surgical risk with a EuroSCORE II of 8.8 ± 6.6. All 50 patients suffered from right-sided HF. Right ventricular systolic function was borderline with a mean tricuspid annular plane systolic excursion of 16 ± 4.1 mm. The aetiology of TR was secondary with a central TR jet in all but one patient. Consistently, the majority of patients suffered from pulmonary hypertension as documented by an increased mean right ventricular-right atrial pressure gradient of 40.6 ± 15.8 mmHg and dilatation of the TV annulus (48 ± 6.8 mm). Mean pulmonary artery pressure measured by right heart catheterization before implantation was 32.5 ± 9.1 mmHg (available for 33 patients). Fourteen patients were treated for isolated TR, while 36 patients were treated for combined MR and TR. At baseline, a significantly lower left ventricular ejection fraction was observed in the combined repair group (43 ± 16% vs. 55 ± 13%, P = 0.01). Patient characteristics are summarized in Table 1 .
In three patients, clip implantation into the TV was unsuccessful. Reasons were insufficient echo views in the first, an excessive Chiari network limiting steerability of the system in a second, and chordal entrapment of the delivery system in a third patient. Among the remaining 47 patients, a successful TV clip implantation with an immediate reduction of at least one grade in TR was achieved in 46 patients. In one patient, clip implantation did not result in a reduction of TR. A total of 95 clips (mean 1.9 per patient) were implanted into the TV. Of these, 80 clips were positioned between the anterior and septal tricuspid leaflets, and 15 were placed between the posterior and septal tricuspid leaflets. The strategy of a clip placement into the antero-septal commissure is supported by a pre-clinical model of edge-to-edge TV repair which demonstrated a more effective TR reduction if the antero-septal commissure was chosen in case of secondary TR. 19 If a significant proportion of the TR jet originated in the postero-septal commissure, clips were also placed into this position.
The discharge TTE showed a mean TR grade of 1.9 ± 0.8 in all patients, with 39 having a TR grade ≤ 2+ (78%) (Figure 1) . In all 36 patients with concomitant clip implantation for severe MR, the percutaneous edge-to-edge repair procedure for the mitral valve could reduce the MR grade from MR ≥3+ to MR ≤2+. In four patients, a significant interatrial shunt through the iatrogenic atrial septum defect was immediately closed by a transcatheter closure device.
Mid-term outcome at 6-month follow-up
The 6-month follow-up rate was 98% (49 of 50 patients) with a median follow-up of 185 (IQR 176-205) days. One patient suffered from stroke 2 weeks after combined MR and TR repair despite sufficient anticoagulation for atrial fibrillation. One patient with an unsuccessful clip placement underwent TV surgery with implantation of an annuloplasty ring 2 weeks after an unsuccessful clipping attempt. Another patient received a mitral valve and TV replacement 7 weeks after the initial procedure due to recurrent severe TR and MR. Two other patients developed recurrent massive TR (4+) within 3 months after the index procedure, one presenting with a partial single-leaflet detachment of one clip. Both patients were treated with repeat clip placement into the TV with . a subsequent TR reduction to grade 3+. Another two patients showed recurrence of TR 4+ within 6 months of follow-up. Of these five patients with recurrence of TR 4+, clips were placed at the index procedure into the antero-septal commissure in three patients and a combination of antero-septal and postero-septal commissure in two patients. Eight patients, including one of the patients undergoing a repeat clip placement, died during follow-up (mortality rate 16%). Three and four patients died in the isolated TR repair group (21%) and combined MR and TR repair group (11%), respectively (P = 0.38; Figure 2 ). Two out of eight patients died within 30 days after the intervention. One patient received his follow-up echocardiogram 158 days after the procedure and died 13 days later, thus he was included in the echocardiographic TR grade analysis. The event-free survival rate from death, transcatheter reintervention and subsequent TV surgery was 78% for all patients (Figure 3) . Over the period of 6 months of follow-up, 14 patients (28% of total) were hospitalized for worsening of HF with right heart decompensation, 5 (36%) and 9 (25%) in the isolated and combined repair group, respectively (P = 0.49). One patient received a biventricular assist device 3 months after clip implantation.
At the latest available follow-up echocardiography at 6 months, TR grade ≤ 2+ was present in 30 out of the 39 patients (77%) who were free of reintervention and death at this time ( Table 2 and Figure 1) . In this group of 39 patients, a persistent reduction of at least one TR grade was achieved in 35 individuals (90%). Both patient groups with isolated tricuspid or combined mitral plus tricuspid valve repair, experienced a comparable TR reduction which was durable over time. A reduction over 6 months of at least one TR grade was achieved in 81% of isolated repair and 93% of combined repair patients (P = 0.561). Rate of TR grade ≤ 2+ was 63% in patients with isolated TV repair and 82% in patients with combined tricuspid and mitral valve repair (P = 0.238) after 6 months. Results were also comparable in patients with and without RV leads. A TR grade ≤ 2+ was present in 83% of patients with a RV lead compared to 74% in patients without a RV lead (P = 0.6927). A persistent reduction of at least one grade in TR was achieved in 91% and 89% of patients with and without a RV lead, respectively (P = 0.5619).
Improvement of at least one NYHA class compared to baseline was achieved in 79% of all patients. The rate of patients in NYHA class ≥III could be reduced from 100% to 36% ( Table 2 and Figure 4) . Again, no significant differences were found between patients treated for isolated TR or combined TR and MR. An improvement of at least one NYHA class was observed in 64% of patients undergoing isolated repair and 86% of patients undergoing combined repair (P = 0.188). The percentage of patients with NYHA class ≥III at 6 months was 45% with isolated repair and 32% with combined repair (P = 0.478).
One patient developed a significant right-to-left shunt at follow-up, which was closed 6 months after the index procedure. In 18 patients, a residual non-significant left-to-right shunt was present. There was no difference in TR grade or NYHA class between patients with and without a residual left-to-right shunt.
The level of NT-proBNP as an established laboratory marker for HF decreased from 3625 (IQR 2229-6931) pg/mL to 2526 (IQR 1261-5303) pg/mL in the overall group (P = 0.002; data from 36 patients available; Table 2 ). In addition, a significant increase was observed in the 6MWD from 191 ± 124 to 275 ± 142 m (P < 0.001; data from 32 patients available; Table 2 ). The improvements were comparable between isolated TR and combined MR and TR treated patients ( Figure 5A and B) . There was a trend towards improvement of quality of life, as assessed by the MLHFQ score, with a decrease from 37 ± 16 to 31 ± 21 points (P = 0.056; data from 36 patients available; Table 2 ). The combined MR and TR repair group seemed to benefit more than the isolated TR repair group ( Figure 5C ). Due to recurrent hospitalizations for right-sided HF with fluid overload, we aimed for a stabilization of diuretic dose to achieve a recompensated fluid balance. As such, in 76% of patients with available information on diuretic medication at follow-up, loop diuretic dose could be stabilized or slightly reduced (33 of 43 patients). In 10 patients, the loop diuretic dose was higher during follow-up compared to baseline. 
Discussion
This retrospective dual-centre study demonstrates the mid-term safety and efficacy of percutaneous edge-to-edge valve repair in patients with severe isolated TR or with concomitant severe MR and TR, who were deemed at prohibitive surgical risk by an interdisciplinary heart team. The implantation of clips into the TV was feasible in 47 out of 50 patients. Echocardiographic evaluation during follow-up showed a reduction of TR by at least one grade from baseline in 90% of patients alive and free of reintervention. The rate of severe TR (≥3+) 6 months after the procedure was 23%. This is comparable to surgical TV repair, after which rates of TR ≥3+ have been reported in up to 20% of operated patients. 20, 21 In four patients a repeat surgical or interventional procedure was necessary due to recurrent TR. This rate of 8% is somewhat higher than the reported rate for repeat TV surgery amounting to approximately 1% to 5%, 21 -23 but in line with reintervention rates after edge-to-edge mitral valve repair for severe MR. 24 The need for repeat procedures is most likely explained by (i) the complex TV anatomy for an interventional approach, (ii) the necessity to develop a new device steering technique, (iii) difficulties in sufficient leaflet grasping, (iv) the demand of adequate procedural echocardiographic imaging, and (v) transfer of a device designed for mitral valve repair to the TV. The majority of these limitations are expected to improve with increasing procedural experience, refined and designated device design as well as advances and standardizations in echocardiographic imaging.
A significant improvement in HF symptoms was observed in patients treated for isolated TR and combined MR and TR. The majority of patients showed improved NYHA class and 6MWD, . and a tendency towards better quality of life. Those results were durable over the 6-month follow-up period. The improvements appear to be comparable for both patient groups, but larger patient populations need to be treated to fully evaluate the impact of interventional tricuspid repair on clinical outcome in right-sided HF patients. Almost all of the treated patients suffered from secondary TR with right-sided HF and 14 patients had isolated percutaneous TV repair for this entity. A desired effect of any therapeutic option in patients with right-sided HF and severe TR beside TR reduction would be the stabilization or recovery of RV function, since RV dysfunction is associated with a worse prognosis in HF patients, irrespective of their left ventricular systolic function. 25, 26 Of note, current guidelines do not recommend surgery for isolated severe secondary TR with right-sided HF. This is based on limited data, where patients with established RV dysfunction did not show any significant improvement in RV function after isolated TV surgery. 20 Due to the few options to ameliorate durably right-sided HF symptoms by medication as well as the lack of surgical treatment options in this high-risk patient population, the interventional 
TR severity ≥3
49 (98) 12 ( edge-to-edge repair approach could be a treatment alternative with potentially improved clinical outcome at least over a 6-month follow-up period. It remains controversial whether moderate TR (2+) in the presence of severe MR should be repaired concomitantly in one procedure, particularly when the tricuspid annulus is dilated >40 mm. Experience from surgery suggests that this might represent a reasonable approach to prevent a second, high-risk operation for a worsening TR in the future, 27 and is thus recommended in international guidelines. 5, 6 Prognostic impact of this combined approach, both surgical and catheter-based, is unknown due to the lack of larger prospective or randomized studies. The treating physician should take into consideration, that moderate TR (2+) might deteriorate depending on the fluid balance leading to recurrent decompensations. Both a staged or a combined catheter-based approach for patients with moderate TR and concomitant severe MR could have potential advantages. A possible benefit of a staged catheter-based repair might be its favourable safety profile compared to a combined or staged surgical approach. As such, a patient with severe MR and at least moderate TR (2+) would undergo an initial catheter-based mitral valve repair procedure. In the absence of TR improvement or even worsening over mid-term, a second . Importantly, recent studies have demonstrated an already increased in-hospital and early mortality in patients who were treated for severe MR by the edge-to-edge repair technique and suffered from concomitant severe or even moderate TR. 28, 29 According to the available literature, one cannot infer a spontaneous improvement of severe TR after edge-to-edge mitral valve repair: a reduction of TR can be seen in less than 50% of patients with moderate to severe TR, 30 actually the percentage of severe TR in this report by Yzeiraj et al. did not change. Another recent study with individual patient data reported an improvement of severe TR after edge-to-edge mitral valve repair in only 18% of patients. 31 Thus, a 'wait and see' approach, assuming a spontaneous reduction of severe TR in all patients, might not be worthwhile considering the worse prognosis associated with severe TR. This could potentially be of particular relevance in patients with left-sided HF with secondary MR, in whom RV dysfunction worsens prognosis substantially. 32 A simultaneous transcatheter treatment of both valve regurgitations might be considered in the future, if this approach is associated with an improved outcome.
Limitations
Although the patient population in this study is still small, it is the first report evaluating the clinical course of consecutive patients treated percutaneously for severe TR over a 6-month period. The study included 36 patients with a simultaneous edge-to-edge repair of severe MR and TR. A core lab analysis of the echocardiographic studies was not performed. We did not include a control group, as the present analysis was not designed to investigate a potential added clinical benefit of transcatheter edge-to-edge repair of TR as compared to conservative treatment alone. 
Conclusion
This dual-centre study suggests that percutaneous edge-to-edge TV repair is feasible and safe. Furthermore, the reduction of TR in patients with severe right-sided HF appears to be associated with a durable improvement in HF symptoms up to 6 months. This improvement was observed in patients treated with isolated TV repair and concomitant mitral and tricuspid valve repair. Based on these results, further randomized studies comparing percutaneous TV repair with optimal medical therapy are warranted to confirm the preliminary clinical impact of this new strategy in HF patients.
